Performance of F-18 Fluorocholine PET/CT for Detection of Hyperfunctioning Parathyroid Tissue in Patients with Elevated Parathyroid Hormone Levels and Negative or Discrepant Results in conventional Imaging.
Adolescent
Adult
Aged
Aged, 80 and over
Choline
/ analogs & derivatives
Female
Humans
Hyperparathyroidism
/ diagnostic imaging
Image Processing, Computer-Assisted
Male
Middle Aged
Parathyroid Glands
/ diagnostic imaging
Parathyroid Hormone
/ metabolism
Parathyroid Neoplasms
/ diagnostic imaging
Parathyroidectomy
Positron Emission Tomography Computed Tomography
Radiopharmaceuticals
/ chemistry
Retrospective Studies
Technetium Tc 99m Sestamibi
/ chemistry
Young Adult
Computed tomography
Fluorocholine
Hyperparathyroidism
Parathyroid adenoma
Positron emission tomography
Tc-99m sestamibi
Journal
Korean journal of radiology
ISSN: 2005-8330
Titre abrégé: Korean J Radiol
Pays: Korea (South)
ID NLM: 100956096
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
14
04
2019
accepted:
22
10
2019
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
17
9
2020
Statut:
ppublish
Résumé
Our aim was to assess the diagnostic performance of F-18 fluorocholine (FCH) positron emission tomography/computed tomography (PET/CT) in detecting hyperfunctioning parathyroid tissue (HPT) in patients with elevated parathyroid hormone levels with negative or inconclusive conventional imaging results and to compare the findings with those obtained using technetium-99m sestamibi (MIBI) scintigraphy and neck ultrasonography (US). Images of 105 patients with hyperparathyroidism who underwent FCH PET/CT, dual-phase MIBI parathyroid scintigraphy (median interval: 42 days), and neck US were retrospectively analyzed. The gold standard was histopathological findings for 81 patients who underwent parathyroidectomy and clinical follow-up findings in the remaining 24 patients. Sensitivities, positive predictive values (PPVs), and accuracies were calculated for all imaging modalities. Among the 81 patients who underwent parathyroidectomy, either parathyroid adenoma (n = 64), hyperplasia (n = 9), neoplasia (n = 4), or both parathyroid adenoma and hyperplasia (n = 1) were detected, except 3 patients who did not show HPT. Of the 24 (23%) patients who were followed-up without operation, 22 (92%) showed persistent hyperparathyroidism. FCH PET/CT showed significantly higher sensitivity than MIBI scintigraphy and US in detection of HPT ( FCH PET/CT is an effective imaging modality for detection of HPT with the highest sensitivity among the available imaging techniques. Therefore, FCH PET/CT can be recommended especially for patients who show negative or inconclusive results on conventional imaging.
Identifiants
pubmed: 31997599
pii: 21.236
doi: 10.3348/kjr.2019.0268
pmc: PMC6992441
doi:
Substances chimiques
Parathyroid Hormone
0
Radiopharmaceuticals
0
fluorocholine
6029HGL0QP
Technetium Tc 99m Sestamibi
971Z4W1S09
Choline
N91BDP6H0X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
236-247Informations de copyright
Copyright © 2020 The Korean Society of Radiology.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
Eur J Radiol. 2015 Sep;84(9):1745-51
pubmed: 26047823
Nucl Med Biol. 2008 Feb;35(2):255-60
pubmed: 18312837
J Clin Endocrinol Metab. 2014 Dec;99(12):4531-6
pubmed: 25215560
J Nucl Med. 1992 Mar;33(3):313-8
pubmed: 1531500
Horm Cancer. 2018 Dec;9(6):440-447
pubmed: 30121878
AJNR Am J Neuroradiol. 2015 Nov;36(11):2147-52
pubmed: 26359150
Clin Nucl Med. 2012 Mar;37(3):223-8
pubmed: 22310246
Cureus. 2015 Dec 23;7(12):e431
pubmed: 26848420
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):658-666
pubmed: 29270788
Radiology. 2017 Aug;284(2):460-467
pubmed: 28121522
Ann Surg Oncol. 2012 Feb;19(2):577-83
pubmed: 21710322
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):751-765
pubmed: 30094461
Nucl Med Commun. 2016 Dec;37(12):1246-1252
pubmed: 27612033
Eur Radiol. 2018 Jun;28(6):2700-2707
pubmed: 29372312
J Nucl Med. 2007 Jul;48(7):1084-9
pubmed: 17574983
JAMA Surg. 2016 Oct 1;151(10):959-968
pubmed: 27532368
J Clin Endocrinol Metab. 2013 Aug;98(8):3111-2
pubmed: 23788686
World J Surg. 2012 Jun;36(6):1335-9
pubmed: 22146947
Indian J Endocrinol Metab. 2017 May-Jun;21(3):399-403
pubmed: 28553594
Endocrinol Jpn. 1987 Dec;34(6):965-8
pubmed: 3450512
Clin Nucl Med. 2017 Dec;42(12):e491-e497
pubmed: 28902729
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2083-9
pubmed: 25063039
Eur J Surg Oncol. 2017 Jan;43(1):133-137
pubmed: 27776943
Cancer Res. 1993 Mar 1;53(5):977-84
pubmed: 8094997
Otolaryngol Head Neck Surg. 2013 Sep;149(3):366-71
pubmed: 23748916
Arch Biochem Biophys. 1995 Nov 10;323(2):313-22
pubmed: 7487093
Radiology. 2012 Sep;264(3):789-95
pubmed: 22798226
Nat Rev Cancer. 2011 Nov 17;11(12):835-48
pubmed: 22089420
Radiol Oncol. 2015 Nov 27;49(4):327-33
pubmed: 26834518
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):393-4
pubmed: 16385408
Clin Nucl Med. 2013 Jun;38(6):456-8
pubmed: 23603587
Medicine (Baltimore). 2015 Oct;94(41):e1701
pubmed: 26469908